From NAFLD to MASLD: transforming steatotic liver disease diagnosis and management DOI Open Access
Paula Iruzubieta, Carolina Jiménez-González, Joaquín Cabezas

et al.

Metabolism and Target Organ Damage, Journal Year: 2025, Volume and Issue: 5(1)

Published: March 8, 2025

The transition from non-alcoholic fatty liver disease (NAFLD) to metabolic dysfunction-associated steatotic (MASLD) represents a significant evolution in the nomenclature of disease. This updated terminology emphasizes dysfunction as central criterion, offering greater precision and improved risk stratification. MASLD broadens scope classification by incorporating individuals with diverse profiles, including lean patients hepatic steatosis, aligns clinical practice multifactorial nature this condition. global adoption creates opportunities for standardization research settings, facilitating multicenter collaborations enhancing development diagnostic tools therapeutic strategies. However, new poses challenges, potential confusion during implementation, cultural linguistic barriers, integration MetALD, need educational initiatives targeting healthcare providers patients. Further efforts are required refine criteria, address implementation seamlessly incorporate into international coding systems. review evaluates key advantages ongoing challenges associated MASLD, providing comprehensive analysis its impact on practice, research, health

Language: Английский

Recent Advances in miRNA-Based Therapy for MASLD/MASH and MASH-Associated HCC DOI Open Access
Sara Carpi, Simona Daniele,

Jacqueline Almeida

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(22), P. 12229 - 12229

Published: Nov. 14, 2024

Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty (NAFLD), is a growing health concern worldwide, affecting more than 1 billion adults. It may progress to metabolic steatohepatitis (MASH), cirrhosis, and ultimately hepatocellular carcinoma (HCC). Emerging evidence has demonstrated the role in this transition of microRNAs (miRNAs), which regulate expression genes associated with lipid metabolism, inflammation, fibrosis, cell proliferation. Specific miRNAs have been identified exacerbate or mitigate fibrotic carcinogenic processes hepatic cells. The modulation these through synthetic mimics inhibitors represents promising therapeutic strategy. Preclinical models that miRNA-based therapies can attenuate reduce inhibit tumorigenesis, thus delaying preventing onset HCC. However, challenges such delivery mechanisms, off-target effects, long-term safety remain be addressed. This review, focusing on recently published preclinical clinical studies, explores pharmacological potential interventions prevent MASLD/MASH progression toward

Language: Английский

Citations

7
Unraveling the Link: Diagnosing Metabolic Dysfunction-Associated Steatotic Liver Disease in the Context of Decompensated Cirrhosis DOI Creative Commons
Mohamed El‐Kassas,

Marwa Khalaf Hassan,

Khalid Al‐Naamani

et al.

Expert Review of Gastroenterology & Hepatology, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 17, 2025

Language: Английский

Citations

0
Serum uric acid trajectories and risk of metabolic dysfunction-associated steatotic liver disease in China: a 2019–2021 cohort health survey DOI Creative Commons

Dan Shi,

Qilong Tan, Yong Zhang

et al.

BMC Public Health, Journal Year: 2025, Volume and Issue: 25(1)

Published: Feb. 17, 2025

Language: Английский

Citations

0
From NAFLD to MASLD: transforming steatotic liver disease diagnosis and management DOI Open Access
Paula Iruzubieta, Carolina Jiménez-González, Joaquín Cabezas

et al.

Metabolism and Target Organ Damage, Journal Year: 2025, Volume and Issue: 5(1)

Published: March 8, 2025

The transition from non-alcoholic fatty liver disease (NAFLD) to metabolic dysfunction-associated steatotic (MASLD) represents a significant evolution in the nomenclature of disease. This updated terminology emphasizes dysfunction as central criterion, offering greater precision and improved risk stratification. MASLD broadens scope classification by incorporating individuals with diverse profiles, including lean patients hepatic steatosis, aligns clinical practice multifactorial nature this condition. global adoption creates opportunities for standardization research settings, facilitating multicenter collaborations enhancing development diagnostic tools therapeutic strategies. However, new poses challenges, potential confusion during implementation, cultural linguistic barriers, integration MetALD, need educational initiatives targeting healthcare providers patients. Further efforts are required refine criteria, address implementation seamlessly incorporate into international coding systems. review evaluates key advantages ongoing challenges associated MASLD, providing comprehensive analysis its impact on practice, research, health

Language: Английский

Citations

0